Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung Cancer
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
Tag: bispecific T-cell engager
Longer Gaps Between Tarlatamab Doses Show Promise in Small Cell Lung Cancer
The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...
Tarlatamab vs. Comparators in Advanced Small Cell Lung Cancer
In the world of oncology, where breakthroughs can define the course of treatment and patient outcomes, a recent study presents ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!